Ivy Parks's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
President
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Government Bill (Senate)- Bill S-5 - Connected Care-An Act respecting the interoperability of health information technology and to prohibit data blocking by health information technology vendors
Public Bill (Senate) S-243- National Framework for Women's Health
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, health system planning and resilience.
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, innovation, women’s health, and investments in long-term care and home care
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, health system planning and resilience.
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
Canadian-United States-Mexico Agreement (CUSMA) with respect to provisions relating to medical devices and technologies
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, women’s health, and investments in long-term care and home care
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing.
Discuss policies around healthcare system resiliency, infection prevention, medication errors, women's health, and health equity
Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies
Economic DevelopmentHealthScience and Technology
Economic DevelopmentGovernment ProcurementHealthIndustryResearch and DevelopmentScience and Technology
Economic DevelopmentHealthResearch and DevelopmentScience and Technology
Health
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.